A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

This is a Phase 3, randomized, positive-controlled, open-label clinical study. The primary objective is to evaluate the efficacy of JMT101 in combination with osimertinib versus osimertinib alone in patients with newly diagnosed locally advanced or metastatic non-squamous NSCLC harboring EGFR-sensitive mutations.

Trial Details

NCT ID
NCT06735391
Phase
PHASE3
Sponsor
Shanghai JMT-Bio Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • JMT101
  • Osimertinib
Locations (sample)
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Be able to understand and voluntarily sign the written informed consent form (ICF);
  • Age ≥ 18 years old, male or female;
  • Participants with histologically or cytologically (pathology report required) confirmed non-squamous NSCLC that is unresectable and locally advance…
  • Participants who have no prior systemic anti-tumor therapy (including anti-EGFR targeted therapy, chemotherapy, biotherapy, immunotherapy, or any i…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →